Abstract
Looking to exploit a natural cellular communication highway, a new company, Codiak BioSciences, has launched with $80 million in venture capital funding to develop exosome-based drugs and diagnosti...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
